A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency. [Estudio clínico en Fase 2, doble ciego, controlado con placebo y aleatorizado de BHQ880, anticuerpo monoclonal (AcM) anti-Dickkopf1 (DKK1), en pacientes con mieloma múltiple no tratado e insuficiencia renal]

Trial Profile

A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency. [Estudio clínico en Fase 2, doble ciego, controlado con placebo y aleatorizado de BHQ880, anticuerpo monoclonal (AcM) anti-Dickkopf1 (DKK1), en pacientes con mieloma múltiple no tratado e insuficiencia renal]

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs BHQ 880 (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 18 Feb 2014 Status changed from active, no longer recruiting to completed.
    • 16 Apr 2013 Planned end date changed from 1 Feb 2015 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 16 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top